Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

BioBone BioBone: Bioactive Hydrogel-based Implants to Induce Bone Regeneration

Coordinator
Tel Aviv University, Israel
Runs
1 March 2024 to 31 August 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
2 organisations in 2 countries
Type
European Research Council grant
Grant agreement
101123407

What the project is doing

In the project's own words, from its summary on CORDIS.

Osteosarcoma and Ewing sarcoma are the most common types of cancer in patients younger than 30 years. The gold standard treatment is bone tumor resection followed by reconstruction of the tissue, thereby allowing the salvage of the limb. Titanium and its alloys are mostly used in such orthopedic surgeries due to their biocompatibility and excellent mechanical properties. A novel, cutting-edge technology of patient-specific implants, 3-dimensional (3D) printed porous titanium implants, was recently introduced to clinical use.

Yet, even several years after surgery, the resected section is not fully reconstructed, leading to further medical complications often requiring re-operations. A promising solution is the combination of titanium porous implants with bioactive scaffolds to support bone regeneration following tumor resection. Here, we aim to fabricate a 3D-printed porous titanium implant incorporated with patent-protected bioactive materials we have developed in the scope of the PersonalBone ERC-StG project to provide an optimal microenvironment for stimulating bone regeneration following bone tumor resection.

For this purpose, we will optimize the formulation as well as the method of incorporation into 3D-printed titanium implants. The incorporated implants will be tested for biocompatibility and osteointegration in critical-size bone defect models in vivo. As we recently demonstrated for the novel materials, we will examine several success criteria, which will be refined according to input from orthopedic oncology surgeons who routinely perform tumor resections.

This novel technology is envisioned to significantly advance the current treatments offered following bone resection, thereby considerably reducing the risk of further complications and offering a major improvement in the quality of life of patients recovering from bone cancer.

Topics

Who is involved

OrganisationCityCountryRole
Tel Aviv UniversityTel AvivIsraelCoordinator
Day One Societa a Responsabilita LimitataRoma RmItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI